Praeventionis et curatio cancer hepatis urget. Traditional curatio cancer iecoris chirurgica est, coniuncta cum radiotherapia et chemotherapy. Tales tractatus traditi methodi magnas limitationes habent. Cum progressu technologiae medicae, quaedam graviores methodi ad tumores tractandos magis magisque in experimentis clinicis adhibentur, sicut yttrium 90 curationis, quae talis est methodus radiotherapiae.
Quid est yttrium 90 microsphaerium?
It is a new method developed by Australia in 1998. It was approved by the US FDA for liver metastasis of colorectal cancer in 2002 and approved by the EU in 2003 for liver cancer patients who cannot be surgically removed. Taiwan was also approved for use in 2011.
Yttrium 90 microspheres are tiny spheres with radioactive material that can emit beta rays, but not primary gamma rays. It can be carried in glass microspheres or lipids, its radiation range is only 1.1 cm, the half-life time is short (about 64 hours), and radioactive yttrium 90 is delivered to the blood vessel supplying tuberculum nutrients through the catheter, and it will stop with the blood flow The tiny arteries that reside in the tumor have a fairly good tumor coverage. Next, local radiotherapy will be performed for about two weeks (β-rays decay with time, emit 94% of the radiation energy within 11 days, and less than 2.5% of the emission energy after 14 days), with close-range, high radiation dose of β- Rays kill liver tumors.
In genere, radiatio externa curationis rationem habet damni, quae circumiectis fibris normalibus sustineri potest, ideo energia 30 grisea tantum attingere potest, et vis radioembolizationis transhepaticae arteriae tam altae quam 150 griseae esse potest. Eodem tempore, usus angiographiae technologiae ad augendam positiones accurationem non solum locales augere potest Tumor lethitas etiam latus effectus curationis minuere potest, et noxa noxia toxico minus gravis est quam chemotherapy, quae efficaciorem effectum curationis consequi potest. .
Vinculum auxiliarium magni momenti in curatione carcinomatis hepatis
After receiving yttrium 90 therapy, some of the iecoris cancer patients who were not suitable for surgery at the beginning narrowed the tumor to the scope of surgery, and finally removed the tumor by surgery. Therefore, yttrium 90 in vivo radiotherapy can not only be used as the main link of liver cancer, but also an important auxiliary link.
Licet yttrium 90 therapia varias utilitates habeat, notandum tamen est aliquos aegros yttrium 90 radiotherapiae vivo non esse, ut aegros cum cholangiocarcinomate, patientibus metastasibus iecoris colorectales, quae manu et chemotherapy non tractabilia sunt, efficax non est. Pectus cancer aegros cum metastasibus hepatis curandis defecerunt cum variis medicamentis chemotherapy.
Simplicius autem suprascripta cognitio yttrium 90 intelligit quedam simplicia in curatione cancri hepatis. Haec nova technica ars notae ad cancer hepatis curationem pertinet. Haec curatio methodus magna auxiliari nexus in curatione cancri hepatis fieri potest. Sane non omnes aegroti yttrium 90 justo apti sunt. Nam aegros cancer iecoris, symptomatica curatio est potissima in processu curationis, et pro uulgo, ne cancer iecoris firmare necesse est.
